These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15504568)

  • 1. Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis.
    Altundag O; Altundag K; Selim Silay Y; Gunduz M; Demircan K; Gullu I
    Med Hypotheses; 2004; 63(6):1010-3. PubMed ID: 15504568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases.
    Amir E; Simmons CE; Freedman OC; Dranitsaris G; Cole DE; Vieth R; Ooi WS; Clemons M
    Cancer; 2010 Jan; 116(2):284-91. PubMed ID: 19918922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
    Chirgwin JM; Guise TA
    Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
    Conte P; Guarneri V
    Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
    Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
    Polyzos SA; Anastasilakis AD; Makras P; Terpos E
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
    Clines GA; Guise TA
    Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and treatment of hypercalcemia of malignancy.
    Clines GA
    Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
    J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer bone metastasis and current small therapeutics.
    Cicek M; Oursler MJ
    Cancer Metastasis Rev; 2006 Dec; 25(4):635-44. PubMed ID: 17160709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.
    Wang-Gillam A; Miles DA; Hutchins LF
    Oncologist; 2008 Jul; 13(7):821-7. PubMed ID: 18614589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in oncology.
    Coleman RE; McCloskey EV
    Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Saad F; Lipton A
    BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
    Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
    Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.